Victor Biton

6.3k total citations
78 papers, 4.1k citations indexed

About

Victor Biton is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Cellular and Molecular Neuroscience. According to data from OpenAlex, Victor Biton has authored 78 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Psychiatry and Mental health, 60 papers in Pediatrics, Perinatology and Child Health and 29 papers in Cellular and Molecular Neuroscience. Recurrent topics in Victor Biton's work include Epilepsy research and treatment (68 papers), Pharmacological Effects and Toxicity Studies (58 papers) and Neuroscience and Neuropharmacology Research (28 papers). Victor Biton is often cited by papers focused on Epilepsy research and treatment (68 papers), Pharmacological Effects and Toxicity Studies (58 papers) and Neuroscience and Neuropharmacology Research (28 papers). Victor Biton collaborates with scholars based in United States, United Kingdom and Germany. Victor Biton's co-authors include Bassel Abou‐Khalil, G. David Rudd, Pamela Doty, Georgia Montouris, Michael R. Sperling, Anne E. Hammer, Ilo E. Leppik, Gregory L. Krauss, Elinor Ben‐Menachem and James J. Cereghino and has published in prestigious journals such as JAMA, Neurology and Epilepsia.

In The Last Decade

Victor Biton

78 papers receiving 3.9k citations

Peers

Countries citing papers authored by Victor Biton

Since Specialization

Citations

This map shows the geographic impact of Victor Biton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Victor Biton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Victor Biton more than expected).

Fields of papers citing papers by Victor Biton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Victor Biton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Victor Biton. The network helps show where Victor Biton may publish in the future.

Co-authorship network of co-authors of Victor Biton

This figure shows the co-authorship network connecting the top 25 collaborators of Victor Biton. A scholar is included among the top collaborators of Victor Biton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Victor Biton. Victor Biton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Perampanel as monotherapy or first adjunctive therapy in pediatric and adult patients with epilepsy: the first United States-based phase IV open-label ELEVATE study 2024 ·Journal of Neurology ·Vineet Punia, Pavel Klein, (unknown), Victor Biton, (unknown), Leock Y. Ngo, (unknown), Manoj Malhotra	1
2	Long‐term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program 2021 ·Epilepsia ·Josemir W. Sander, William E. Rosenfeld, Jonathan J. Halford, Bernhard J. Steinhoff, Victor Biton, Manuel Toledo	30
3	Post hoc analysis of a phase 3, multicenter, open‐label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications 2021 ·Epilepsia ·William E. Rosenfeld, Bassel Abou‐Khalil, Sami Aboumatar, Perminder Bhatia, Victor Biton, Gregory L. Krauss, Michael R. Sperling, David G. Vossler, Pavel Klein, Robert Wechsler	42
4	Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open‐label study 2021 ·Epilepsia ·Michael R. Sperling, Bassel Abou‐Khalil, Sami Aboumatar, Perminder Bhatia, Victor Biton, Pavel Klein, Gregory L. Krauss, David G. Vossler, Robert Wechsler, (unknown), (unknown), William E. Rosenfeld	40
5	Dose Adjustments to Concomitant Antiseizure Medications: Post-hoc Analysis of a Phase 3, Open-Label Study of Cenobamate for Treatment of Uncontrolled Focal Seizures (1755) 2021 ·Neurology ·William E. Rosenfeld, Bassel Abou‐Khalil, Sami Aboumatar, Perminder Bhatia, Victor Biton, Pavel Klein, Gregory L. Krauss, Michael R. Sperling, David G. Vossler, Robert Wechsler	2
6	Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures 2018 ·Epilepsy & Behavior ·Eva Andermann, Victor Biton, Selim R. Benbadis, Bassel F. Shneker, Aashit Shah, Mar Carreño, Eugen Trinka, Elinor Ben‐Menachem, Arnaud Biraben, (unknown), Helena Gama, Hailong Cheng, David Blum	11
7	Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials 2017 ·Epilepsy & Behavior ·Victor Biton, Joanne Rogin, Gregory L. Krauss, Bassel Abou‐Khalil, José Rocha, (unknown), Helena Gama, Eugen Trinka, Christian E. Elger, Hailong Cheng, Todd Grinnell, David Blum	42
8	Safety and tolerability of different titration rates of retigabine (ezogabine) in patients with partial-onset seizures 2013 ·Epilepsy Research ·Victor Biton, António Gil‐Nagel, Martin J. Brodie, Sarah E. DeRossett, Virinder Nohria	15
9	Long-Term Tolerability and Safety of Lamotrigine Extended-Release: Pooled Analysis of Three Clinical Trials 2013 ·Clinical Drug Investigation ·Victor Biton, Bassel F. Shneker, Dean K. Naritoku, Anne E. Hammer, Alain Vuong, Paul T. Caldwell, John A. Messenheimer	14
10	A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: Efficacy and tolerability in a double-blind, randomized, controlled clinical trial 2012 ·Diabetes Research and Clinical Practice ·(unknown), (unknown), Victor Biton, Verne E. Cowles	28
11	Tolerability and safety of perampanel: two randomized dose-escalation studies 2011 ·Acta Neurologica Scandinavica ·Gregory L. Krauss, Michal Bar, Victor Biton, J. A. Klapper, Ivan Rektor, Nerija Vaičienė-Magistris, David Squillacote, Dinesh Kumar	82
12	Lacosamide for the treatment of diabetic neuropathic pain 2008 ·Expert Review of Neurotherapeutics ·Victor Biton	11
13	Efficacy and Safety of Oral Lacosamide as Adjunctive Therapy in Adults with Partial‐Onset Seizures 2007 ·Epilepsia ·Elinor Ben‐Menachem, Victor Biton, Dalius Jatužis, Bassel Abou‐Khalil, Pamela Doty, G. David Rudd	373
14	Weight Change and Antiepileptic Drugs 2006 ·The Neurologist ·Victor Biton	11
15	Zonisamide: newer antiepileptic agent with multiple mechanisms of action 2004 ·Expert Review of Neurotherapeutics ·Victor Biton	16
16	A dosing algorithm for converting from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy 2004 ·Epilepsy & Behavior ·Mark Sale, (unknown), Victor Biton, Alain Vuong, Anne E. Hammer, John A. Messenheimer, David Blum	6
17	Divalproex-ER pharmacokinetics in older children and adolescents 2004 ·Pediatric Neurology ·Sandeep Dutta, Yiming Zhang, Jeannine M. Conway, Floyd R. Sallee, Victor Biton, Michael D. Reed, Gregory L. Kearns	21
18	Effect of Antiepileptic Drugs on Bodyweight 2003 ·CNS Drugs ·Victor Biton	90
19	Efficacy and Safety of Recombinant Human Nerve Growth Factor in Patients With Diabetic Polyneuropathy 2000 ·JAMA ·Stuart C. Apfel, (unknown), Bruce T. Adornato, Roy Freeman, Victor Biton, Marc Rendell, Aaron I. Vinik, Michael J. Giuliani, J. Clarke Stevens, Richard L. Barbano, Peter James Dyck	274
20	Adjunctive Therapy for Intractable Epilepsy with Ethotoin 1990 ·Epilepsia ·Victor Biton, John R. Gates, Frank J. Ritter, Ruth B. Loewenson	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact